CD4 and inflammatory bowel disease: Therapeutically, CD4+ T cell-depleting and blocking antibodies (cM-T412, MAX.16H5, and B-F5) have been shown to induce remission in both CD and UC patients (25, 26), while alternate therapies that inhibit the differentiation of CD4+ T cell subsets and the cytokines they secrete, have proven to be efficacious in IBD patients, These would include Tofacitinib (oral JAK inhibitor), Ustekinumab (human monoclonal antibody directed against IL-12 and Il-23) and Infliximab (chimeric hiamn/mouse monoclonal antibody directed against TNFα) (27–33).